{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T23:40:58Z","timestamp":1792194058582,"version":"4.4.0"},"reference-count":8,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T00:00:00Z","timestamp":1792108800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T00:00:00Z","timestamp":1792108800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Hematol Oncol"],"DOI":"10.1186\/s13045-026-01851-1","type":"journal-article","created":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T22:47:15Z","timestamp":1792190835000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["AXL-directed antibody\u2013drug conjugate therapy in soft-tissue sarcoma"],"prefix":"10.1186","volume":"19","author":[{"given":"Nathan","family":"El-Ghazzi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tony","family":"Sourisseau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vanessa","family":"Chaire","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tom","family":"Del Ben","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie-Alix","family":"Derieppe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucile","family":"Vanhersecke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christophe","family":"Rey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alban","family":"Bessede","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Max","family":"Pasquet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antoine","family":"Italiano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,10,16]]},"reference":[{"key":"1851_CR1","doi-asserted-by":"publisher","first-page":"901","DOI":"10.1186\/s12885-015-1916-3","volume":"15","author":"CD May","year":"2015","unstructured":"May CD, Garnett J, Ma X, Landers SM, Ingram DR, Demicco EG, et al. AXL is a potential therapeutic target in dedifferentiated and pleomorphic liposarcomas. BMC Cancer. 2015;15:901. https:\/\/doi.org\/10.1186\/s12885-015-1916-3.","journal-title":"BMC Cancer"},{"key":"1851_CR2","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1186\/s13046-023-02726-w","volume":"42","author":"Y Tang","year":"2023","unstructured":"Tang Y, Zang H, Wen Q, Fan S. AXL in cancer: a modulator of drug resistance and therapeutic target. J Exp Clin Cancer Res. 2023;42:148. https:\/\/doi.org\/10.1186\/s13046-023-02726-w.","journal-title":"J Exp Clin Cancer Res"},{"key":"1851_CR3","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1158\/1535-7163.MCT-21-0715","volume":"21","author":"F Zammarchi","year":"2022","unstructured":"Zammarchi F, Havenith KEG, Chivers S, Hogg P, Bertelli F, Tyrer P, et al. Preclinical development of ADCT-601, a novel pyrrolobenzodiazepine dimer-based antibody\u2013drug conjugate targeting AXL-expressing cancers. Mol Cancer Ther. 2022;21:582\u201393. https:\/\/doi.org\/10.1158\/1535-7163.MCT-21-0715.","journal-title":"Mol Cancer Ther"},{"key":"1851_CR4","doi-asserted-by":"publisher","first-page":"7493","DOI":"10.3390\/ijms23147493","volume":"23","author":"B Van Renterghem","year":"2022","unstructured":"Van Renterghem B, Wozniak A, Castro PG, Franken P, Pencheva N, Sciot R, et al. Enapotamab vedotin, an AXL-specific antibody\u2013drug conjugate, demonstrates antitumor efficacy in patient-derived xenograft models of soft tissue sarcoma. Int J Mol Sci. 2022;23:7493. https:\/\/doi.org\/10.3390\/ijms23147493.","journal-title":"Int J Mol Sci"},{"key":"1851_CR5","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1093\/abt\/tbaf006","volume":"8","author":"HW Chang","year":"2025","unstructured":"Chang HW, Wang J, Liu H, Xing C, Chen J, Frey G, et al. Preclinical development of mecbotamab vedotin (BA3011), a novel AXL-specific conditional active biologic antibody\u2013drug conjugate. Antib Ther. 2025;8:145\u201356. https:\/\/doi.org\/10.1093\/abt\/tbaf006.","journal-title":"Antib Ther"},{"key":"1851_CR6","doi-asserted-by":"publisher","first-page":"102443","DOI":"10.1016\/j.esmoop.2024.102443","volume":"9","author":"S Pollack","year":"2024","unstructured":"Pollack S, Conley AP, Tap WD, Yen CC, Charlson J, Davis LE, et al. Results from a phase II part I trial of mecbotamab vedotin (BA3011), a CAB-AXL-ADC, in patients with advanced refractory sarcoma. ESMO Open. 2024;9:102443. https:\/\/doi.org\/10.1016\/j.esmoop.2024.102443.","journal-title":"ESMO Open"},{"key":"1851_CR7","doi-asserted-by":"publisher","first-page":"2066","DOI":"10.1158\/2767-9764.CRC-25-0359","volume":"5","author":"KS Rohrberg","year":"2025","unstructured":"Rohrberg KS, Lopez JS, Milhem MM, Blank CU, Reijers I, Thistlethwaite F, et al. Phase I\/II study of AXL-specific antibody\u2013drug conjugate enapotamab vedotin in patients with advanced solid tumors. Cancer Res Commun. 2025;5:2066\u201378. https:\/\/doi.org\/10.1158\/2767-9764.CRC-25-0359.","journal-title":"Cancer Res Commun"},{"key":"1851_CR8","unstructured":"Therapeutics ADC. Nov. ADC Therapeutics reports third quarter and year-to-date 2024 financial results and provides operational update. 7 2024. https:\/\/ir.adctherapeutics.com\/2024-11-07-ADC-Therapeutics-Reports-Third-Quarter-and-Year-to-Date-2024-Financial-Results-and-Provides-Operational-Update. Accessed 13 Aug 2026."}],"container-title":["Journal of Hematology &amp; Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13045-026-01851-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13045-026-01851-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13045-026-01851-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T22:47:16Z","timestamp":1792190836000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13045-026-01851-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,16]]},"references-count":8,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1851"],"URL":"https:\/\/doi.org\/10.1186\/s13045-026-01851-1","relation":{},"ISSN":["1756-8722"],"issn-type":[{"value":"1756-8722","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,16]]},"assertion":[{"value":"20 July 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 September 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 October 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Human tissue: Sarcoma cell lines and tissue-microarray specimens were derived from human surgical samples collected at Institut Bergoni\u00e9 after written informed consent and approval by the Institutional Review Board of Institut Bergoni\u00e9. Animal work: All animal experiments were approved by the Structure du Bien-\u00catre Animal, Universit\u00e9 de Bordeaux, under protocol DAP #27630 and were performed in accordance with French and European Union regulations. The maximal tumor burden permitted by the approved protocol was 2,000\u00a0mm\u00b3, and this limit was not exceeded.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":3,"name":"Ethics","label":"Authors\u2019 information","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"88"}}